IRIS UniCatt

Chiloiro, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.955
AS - Asia 2.641
EU - Europa 2.095
SA - Sud America 869
AF - Africa 90
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 8.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.800
SG - Singapore 1.257
BR - Brasile 716
CN - Cina 633
IT - Italia 432
DE - Germania 421
SE - Svezia 324
VN - Vietnam 252
FR - Francia 154
GB - Regno Unito 128
FI - Finlandia 110
RU - Federazione Russa 109
IE - Irlanda 102
ID - Indonesia 98
PL - Polonia 84
IN - India 83
CA - Canada 71
UA - Ucraina 65
AR - Argentina 63
MX - Messico 53
HK - Hong Kong 47
AT - Austria 39
BD - Bangladesh 36
ZA - Sudafrica 35
NL - Olanda 33
JP - Giappone 31
TR - Turchia 30
IQ - Iraq 27
KR - Corea 23
EC - Ecuador 22
BE - Belgio 21
ES - Italia 21
VE - Venezuela 19
AE - Emirati Arabi Uniti 16
PK - Pakistan 15
IR - Iran 14
EG - Egitto 13
SA - Arabia Saudita 13
UZ - Uzbekistan 12
CL - Cile 11
CO - Colombia 11
PY - Paraguay 11
PE - Perù 10
CI - Costa d'Avorio 8
LT - Lituania 8
MA - Marocco 8
JO - Giordania 7
KE - Kenya 7
AL - Albania 6
DO - Repubblica Dominicana 6
LK - Sri Lanka 6
PT - Portogallo 6
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
KZ - Kazakistan 5
RO - Romania 5
CH - Svizzera 4
ET - Etiopia 4
HN - Honduras 4
IL - Israele 4
JM - Giamaica 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
PA - Panama 4
RS - Serbia 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BB - Barbados 3
GE - Georgia 3
KG - Kirghizistan 3
NP - Nepal 3
OM - Oman 3
PH - Filippine 3
TN - Tunisia 3
AM - Armenia 2
AU - Australia 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BS - Bahamas 2
DZ - Algeria 2
GR - Grecia 2
LB - Libano 2
MY - Malesia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AQ - Antartide 1
BW - Botswana 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GU - Guam 1
HU - Ungheria 1
LI - Liechtenstein 1
LV - Lettonia 1
ML - Mali 1
Totale 8.649
Salva come PNG Salva come JPEG
Città #
Singapore 580
Chandler 410
Ashburn 294
Beijing 158
New York 150
Rome 133
Los Angeles 117
Ho Chi Minh City 99
Hefei 96
Dublin 89
São Paulo 80
Ann Arbor 78
Jakarta 78
Warsaw 76
The Dalles 74
Munich 72
Moscow 68
Fairfield 67
Milan 59
San Mateo 57
Dallas 53
Wilmington 52
Boston 49
Hanoi 48
Frankfurt am Main 47
Hong Kong 45
Bremen 44
Chicago 44
Helsinki 43
Kent 43
Seattle 41
Cattolica 40
Turku 40
Houston 39
Marseille 37
Montreal 36
Denver 34
Princeton 34
London 31
Nanjing 27
Rio de Janeiro 27
Brooklyn 26
Santa Clara 26
Orem 25
Jacksonville 24
Nuremberg 24
Buffalo 23
Seoul 22
Woodbridge 22
Hyderabad 21
Brussels 20
Cambridge 19
Tokyo 19
North Bergen 18
Atlanta 17
Belo Horizonte 17
Boardman 17
Johannesburg 17
Lappeenranta 17
Mexico City 17
Stockholm 17
Vienna 16
Phoenix 15
Hangzhou 14
Poplar 14
Redmond 14
Redwood City 13
Augusta 12
Baghdad 12
Lauterbourg 12
Mountain View 12
Porto Alegre 12
Querétaro 12
Ankara 11
Bexley 11
Dearborn 11
Hải Dương 11
Norwalk 11
Da Nang 10
Lawrence 10
Manchester 10
Tashkent 10
Zhengzhou 10
Amsterdam 9
Chennai 9
Goiânia 9
Guangzhou 9
Kunming 9
Nürnberg 9
Toronto 9
Abidjan 8
Canoas 8
Curitiba 8
Dhaka 8
Guayaquil 8
Haiphong 8
Izmir 8
Kish 8
Mumbai 8
Piacenza 8
Totale 4.503
Salva come PNG Salva come JPEG
Nome #
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 277
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 277
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 187
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 179
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 156
Xanthogranuloma of the sellar region: A rare tumor. Case illustration and literature review 152
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. 140
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 135
The Changing Clinical Spectrum of Hypophysitis 135
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 128
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 126
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 122
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 120
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 115
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 114
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 114
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 110
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 110
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 107
Empty sella syndrome: Multiple endocrine disorders. 102
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 100
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 98
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 98
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 97
Pediatric craniopharyngiomas: magnetic resonance imaging assessment for hypothalamus-pituitary axis dysfunction and outcome prediction 96
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review 94
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 93
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 92
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 91
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 90
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 90
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 89
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 89
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 88
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 87
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 87
Hypothalamitis and pituitary atrophy 87
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 86
Understanding the effect of acromegaly on the human skeleton. 86
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 85
Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature 84
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 83
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 82
Gut Microbiota, LADA, and Type 1 Diabetes Mellitus: An Evolving Relationship 80
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 80
Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors 79
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 78
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 77
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 77
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 76
Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview 75
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 73
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 73
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 73
The immune microenviroment in somatotropinomas: from biology to personalized and target therapy 73
Temporoparietal Fascia Flap (TPFF) in Extended Endoscopic Transnasal Skull Base Surgery: Clinical Experience and Systematic Literature Review 72
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 72
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 71
Acromegaly can be cured by first-line pasireotide treatment? 70
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 69
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 68
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 68
Acromegaly in the elderly patients 67
Letter: A Multicenter, Propensity Score- Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas 66
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 65
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 64
Empty sella syndrome: an update 64
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 64
De-escalation treatment with pasireotide for acromegaly: a long-term experience 63
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 62
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 62
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 61
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 61
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 61
Consensus on criteria for acromegaly diagnosis and remission 61
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 59
Interpretable Machine Learning-Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study 59
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 59
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 59
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 58
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 57
Reliability of intraoperative visual evoked potentials (iVEPs) in monitoring visual function during endoscopic transsphenoidal surgery 56
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 56
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 53
Hypophysitis in COVID-19: a systematic review 53
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 52
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 51
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 50
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 50
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 49
The Role of Testosterone in Spermatogenesis: Lessons From Proteome Profiling of Human Spermatozoa in Testosterone Deficiency 46
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 46
The curious case of headaches and Rathke’s cleft cysts 45
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 42
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 41
Artificial Intelligence for Individualized Radiological Dialogue: The Impact of RadioBot on Precision-Driven Medical Practices 40
From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management? 40
Vitamin D in pituitary driven osteopathies 39
Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool 38
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 37
Totale 8.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 11 23 2 26 28 28 2
2021/2022474 20 11 6 37 76 25 9 85 23 21 54 107
2022/20231.087 132 153 78 190 56 161 61 78 103 19 27 29
2023/2024658 31 121 23 31 35 113 28 10 39 40 85 102
2024/20251.939 37 42 122 81 91 70 38 54 237 193 449 525
2025/20263.704 773 251 483 994 921 282 0 0 0 0 0 0
Totale 8.816